ACTRIS: A new national enabler for cell and gene therapies in Singapore
ABOUT US

WE ARE ACTRIS

The Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), was established on 20 April 2020 to meet the increasing demand of cellular therapy process development and product manufacturing to enable clinical utility.

ACTRIS’s vision is to be the national and regional Centre of Excellence for facilitating discovery, process development and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine encompassing investigational and approved cellular therapeutics.

NEWSROOM
ACTRIS: A new national enabler for cell and gene therapies in Singapore

ACTRIS: A new national enabler for cell and gene therapies in Singapore

World Cancer Research Day is commemorated each year on 24 September and seeks to raise awareness of the importance of cancer research to increase survival, facilitate access to scientific advances worldwide and reduce the global burden of cancer. Cancer is the second leading cause of death worldwide, and the global burden of cancer continues to […]

READ MORE
Launch of a New National Consortium to Advance Clinical Research and Innovation for Singapore

Launch of a New National Consortium to Advance Clinical Research and Innovation for Singapore

Launch of a New National Consortium to Advance Clinical Research and Innovation for Singapore A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022  CRIS brings together five key national R&D, clinical translation […]

READ MORE
CRIS Scientific Symposium 2022 – Advancing Clinical Research and Innovation in Singapore

CRIS Scientific Symposium 2022 – Advancing Clinical Research and Innovation in Singapore

Join us at the inaugural scientific symposium organised by the Consortium for Clinical Research and Innovation, Singapore (CRIS) on Wed 6 April 2022. Delve into the future of clinical research and healthcare innovation with topics such as Singapore’s National Precision Medicine strategy, leading-edge cell therapy technologies, how to enable sustainability in cancer research, and catalyse clinical […]

READ MORE
[ANNOUNCEMENT] Appointment of CEO (CRIS) and ED (SCRI)

[ANNOUNCEMENT] Appointment of CEO (CRIS) and ED (SCRI)

About the Consortium for Clinical Research and Innovation Singapore (CRIS) The Consortium for Clinical Research and Innovation Singapore (CRIS), a wholly owned subsidiary of MOH Holdings, has been established in 2020 with the goal of strengthening synergies and promulgating strategies for national-level clinical research and translation programmes that are under the stewardship of the Ministry of Health (MOH). […]

READ MORE
VIEW ALL NEWS